These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

605 related items for PubMed ID: 15818594

  • 1. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN, Leung HY.
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [Abstract] [Full Text] [Related]

  • 2. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 3. GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas.
    Szabó J, Bartók K, Krenács T, Szepesváry Z, Szende B.
    Anticancer Res; 2009 Feb 01; 29(2):681-4. PubMed ID: 19331222
    [Abstract] [Full Text] [Related]

  • 4. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4398-405. PubMed ID: 15240528
    [Abstract] [Full Text] [Related]

  • 5. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 6. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov 15; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 7. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
    Lissoni P, Vigano P, Vaghi M, Frontini L, Giuberti C, Manganini V, Casu M, Brivio F, Niespolo R, Strada G.
    Anticancer Res; 2005 May 15; 25(5):3597-9. PubMed ID: 16101186
    [Abstract] [Full Text] [Related]

  • 9. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M, Rossi D, Mabrouk K, Figarella-Branger D, Martin PM, Ouafik L.
    Oncogene; 2008 Jan 17; 27(4):506-18. PubMed ID: 17637748
    [Abstract] [Full Text] [Related]

  • 10. Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease.
    Berruti A, Mosca A, Porpiglia F, Bollito E, Tucci M, Vana F, Cracco C, Torta M, Russo L, Cappia S, Saini A, Angeli A, Papotti M, Scarpa RM, Dogliotti L.
    J Urol; 2007 Sep 17; 178(3 Pt 1):838-43; quiz 1129. PubMed ID: 17631319
    [Abstract] [Full Text] [Related]

  • 11. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, Chiba Prostate Study Group.
    Urology; 2004 Aug 17; 64(2):341-5. PubMed ID: 15302491
    [Abstract] [Full Text] [Related]

  • 12. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
    Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL.
    Cancer Res; 2005 Dec 15; 65(24):11565-71. PubMed ID: 16357166
    [Abstract] [Full Text] [Related]

  • 13. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
    Pályi I, Vincze B, Kálnay A, Turi G, Mezõ I, Teplán I, Seprõdi J, Pató J, Móra M.
    Cancer Detect Prev; 1996 Dec 15; 20(2):146-52. PubMed ID: 8706040
    [Abstract] [Full Text] [Related]

  • 14. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
    Montagnani Marelli M, Moretti RM, Mai S, Procacci P, Limonta P.
    Int J Oncol; 2007 Jan 15; 30(1):261-71. PubMed ID: 17143537
    [Abstract] [Full Text] [Related]

  • 15. Gonadotropin-releasing hormone in apoptosis of prostate cancer cells.
    Kraus S, Naor Z, Seger R.
    Cancer Lett; 2006 Mar 28; 234(2):109-23. PubMed ID: 16546667
    [Abstract] [Full Text] [Related]

  • 16. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N, Arima K, Sugimura Y.
    Jpn J Clin Oncol; 2008 Sep 28; 38(9):617-22. PubMed ID: 18697759
    [Abstract] [Full Text] [Related]

  • 17. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
    Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M.
    Cancer Res; 1994 Aug 01; 54(15):4091-5. PubMed ID: 8033142
    [Abstract] [Full Text] [Related]

  • 18. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
    Wells A, Souto JC, Solava J, Kassis J, Bailey KJ, Turner T.
    Clin Cancer Res; 2002 Apr 01; 8(4):1251-7. PubMed ID: 11948140
    [Abstract] [Full Text] [Related]

  • 19. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M, Latham DE, Delaney MA, Chakravarti A.
    Oncogene; 2005 Apr 07; 24(15):2474-82. PubMed ID: 15735703
    [Abstract] [Full Text] [Related]

  • 20. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A, Di Silverio F.
    Urology; 2004 Mar 07; 63(3):523-7. PubMed ID: 15028450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.